Since 2015, Dr. Toren has worked as a clinician-scientist in the Department of Surgery at Laval University, where his laboratory focuses on translational prostate cancer research. He completed his medical training at Queen’s University in Kingston, Ontario, urology residency and a clinical uro-oncology fellowship at the University of Toronto. Subsequently, he completed a two-year research fellowship at the Vancouver Prostate Centre, under the mentorship of Dr. Martin Gleave. Concurrently, he enrolled in, and recently completed a doctorate in experimental medicine in Dr. Amina Zoubeidi’s laboratory.
The influence of sex steroids on the tumor environment
Androgens and estrogens are important to prostate cancer progression and treatment resistance. Through the analysis of various sex steroids such as testosterone and estrogens, we seek to better understand the hormonal changes which occur following treatment in prostate cancer patients. Further, we seek to understand how differences in these levels between patients may be used to classify them for optimal treatments and understand resistance patterns. We use laboratory models to understand the effect of sex steroids on the local immune environment and production of cytokines regulating the survival and growth of prostate cancer.
Extracellular vesicles as biomarkers
Extracellular vesicles, such as exosomes, are tiny parts of cells which may be detected in many biological fluids, including urine and blood. Using samples from prostate cancer patients, we seek to optimize isolation, enumeration, and characterization techniques. Versatile and containing a significant amount of information pertinent to cancer type and function, these tiny particles may eventually be used to monitor information about responsiveness to treatments through a simple blood test.
1401, 18e rue
Canada G1J 1Z4
- [ULaval Nouvelles] Cancer de la prostate : des avancées du côté de la résistance aux traitements hormonaux 2022-12-05
- Une subvention d’un demi-million de dollars pour le repositionnement de médicaments 2022-10-31
- Près de 9,4 millions de subventions des IRSC pour les projets de 14 chercheurs du CRCHU 2021-08-03
- Gris, TyphaineEmployeeHôpital de l'Enfant-Jésus+1 418-525-4444, extension firstname.lastname@example.org
1401, 18e rue
Canada G1J 1Z4
- Trépanier, GenevièveMaster studentL'Hôtel-Dieu de Québec+1 418-525-4444, extension email@example.com
9 rue McMahon
0885 / 1875
Canada G1R 3S3
Prostate cancer resistance leads to a global deregulation of translation factors and unconventional translationJournal Article
NAR Cancer, 4 (4), 2022.
Analysis of sex-based differences to Bacillus Calmette-Guérin for non-muscle invasive bladder cancerJournal Article
Urol Oncol, 40 (12), 2022.
Combining Antiandrogens with Immunotherapy for Bladder Cancer TreatmentJournal Article
Eur Urol Open Sci, 43 , 2022.
Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen LevelJournal Article
J Urol, 208 (6), 2022.
Patients' perceptions on active surveillance for the treatment of small renal massesJournal Article
Urol Oncol, 40 (11), 2022.
Perception and satisfaction of patients after telemedicine urology consultations: A matched analysis with physicians' perspectiveJournal Article
Can Urol Assoc J, 16 (10), 2022.
Sex steroid modulation of macrophages within the prostate tumor microenvironmentJournal Article
Am J Clin Exp Urol, 10 (2), 2022.
Opioid use after uro-oncologic surgeries in time of opioid crisisJournal Article
Can Urol Assoc J, 16 (8), 2022.
Case - Gigantic obstructive calculi in continent urinary diversionJournal Article
Can Urol Assoc J, 16 (7), 2022.
Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomyJournal Article
Clin Nutr ESPEN, 47 , 2022.
- Exploiter les interactions endocriniennes-immunes pour améliorer le traitement des cancers urologiques, from 2022-07-01 to 2024-06-30
- Repurposing bicalutamide to improve the response to immune checkpoint inhibition for treatment of advanced urothelial carcinoma, from 2022-08-01 to 2026-07-31
- Targeting sex steroids to improve the response to bladder cancer immunotherapy, from 2021-10-01 to 2026-09-30
Recently finished projects
- (FRSQ 91289) Androgen-receptor dependent changes in human bladder cancer macrophages.” , from 2019-09-04 to 2021-09-03
- A study of macrophages as predictors of prostate cancer radiotherapy response , from 2022-01-26 to 2023-01-25
- Development of next-generation biomarkers for prostate cancer treatment, from 2019-07-01 to 2021-12-31
- Sex steroids as modulators of the prostate cancer immune microenvironment, from 2018-09-01 to 2021-08-31